Drug discovery for overcoming chronic kidney disease (CKD): The endothelin etB receptor / nitric oxide system functions as a protective factor in CKD

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 7-13

  Ohkita, Mamoru ^a   Takaoka, Masanori ^a   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chronic kidney disease (CKD); Endothelin 1 (ET 1); ETb receptor; Nitric oxide (NO); Nitric oxide synthase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; DISEASE EXACERBATION; DIURESIS; DRUG SELECTIVITY; DYSLIPIDEMIA; GLOMERULUS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; NATRIURESIS; NONHUMAN; RENAL PROTECTION; RISK REDUCTION; SHORT SURVEY; UPREGULATION;

EID: 58649123608     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R10FM     Document Type: Short Survey

References (71)

1. Sarnak MJ, Levey AS, Scoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050-1065.
2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85- 97.
3. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13 5 Suppl:I80-I93.
4. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034-2047.
5. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease:what do we know? What do we need to learn? Where do we go from here? National Kideny Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
6. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8-20.
7. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: patho- genesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576.
8. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000;15:953-960.
9. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kideny Int. 2001;59:407-414.
10. Vaziri ND, Oveisi F, Ding YX. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53:1748-1754.
11. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
12. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol. 2008;294:F1-F9.
13. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186-1193.
14. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17:943-955.
15. Tizianello A, De Ferrari G, Garibotto G, Gurreri G, Robaudo C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest. 1980;65:1162-1173.
16. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001;59:1466-1472.
17. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant. 2003;18:2415-2420.
18. Reyes AA, Purkerson ML, Karl I, Klahr S. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kideny Dis. 1992;20:168-176.
19. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kideny Int. 1995;47:1515-1521.
20. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989;35:654-660.
21. Fujihara CK, De Nucci G, Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol. 1995;5:1498-1507.
22. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96:953-964.
23. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
24. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006;17:2176-2183.
25. Yamamizu K, Shinozaki K, Ayajiki K, Gemba M, Okamura T. Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunction in rats with chronic renal failure. J Cardiovasc Pharmcol. 2007;49:131-139.
26. Yamashita C, Tazawa N, Ohkita M, Matsumura Y. Exaggerated renal pathology of partial ablation-induced chronic renal failure in eNOS deficient mice. Biol Pharm Bull. 2008;31:1029-1031
27. Wagner L, Riggleman A, Erdely A, Couser W, Baylis C. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int. 2002;62:532- 536.
28. Erdely A, Freshour G, Smith C, Engels K, Olson JL, Baylis C. Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. Am J Physiol Renal Physiol. 2004;287:F81-F89.
29. Erdely A, Wagner L, Muller V, Szabo A, Baylis C. Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol. 2003;14:2526-2533.
30. Szabo AJ, Wagner L, Erdely A, Lau K, Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int. 2003;64:1765-1771.
31. Muller V, Engels K, Baylis C. Chronic inhibition of nitric oxide synthase (NOS) renders the C57BL6 mouse susceptible to the development of chronic renal disease (Abstract). J Am Soc Nephrol. 2003;14:625A.
32. Tain YL, Croker B, Muller V, Baylis C. Impact of chronic inhibition of neuronal nitric oxide synthase (nNOSI) and knockout (ko) of the endothelial (e)NOS on chronic kidney disease (CKD) in mouse (Abstract). J Am Soc Nephrol. 2007;18:182A.
33. Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi L, Gabanelli M, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 1991;260:F331-F339.
34. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993;43:354-358.
35. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
36. Brochu E, Lacasse M, Moreau S, Lebel C, Kingma M, Grose I, et al. Endothelin ETA receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant. 1999;14:1881-1888.
37. Lebel M, Grose JH, Kingma I, Langlois S. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients: effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens. 1994;16:565-575.
38. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol. 1996;72:261-290.
39. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47:731-759.
40. Nabokov A, Amann K, Wagner J, Gehlen F, Munter K, Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant. 1996;11:514-520.
41. Nabokov A, Amann K, Wessels S, Munter K, Wagner J, Ritz E. Endothelinreceptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 1999;55:512-519.
42. Shimizu T, Hata S, Kuroda T, Mihara S, Fujimoto M. Different roles of two type of endothelin receptors in partial ablation-induced chronic renal failure in rats. Eur J Pharmaccol. 1999;381:39-49.
43. Pollock DM, Polakowski JS. ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in th rat. J Am Soc Nephrol. 1997;8:1054-1060.
44. Gariepy CE, Cass DT, Yanagisawa M. Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci USA. 1996;93:867-872.
45. Tazawa N, Okada Y, Nakata M, Izumoto H, Takasu M, Takaoka M, et al. Exaggerated vascular and renal pathology in endothelin-B-receptor-deficient rats with subtotal nephrectomy. J Cardio-vasc Pharmacol. 2004;44 Suppl 1:S467-S470.
46. b receptor in partial ablation- induced chronic renal failure in rats. Eur J Pharmacol. 2004;494:63-71.
47. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-252.]
48. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003;63:2254-2261.
49. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540- 1546.
50. Fogo AB. Progression and potential regression of glomerulo- sclerosis. Kidney Int. 2001;59:804-819.
51. Fogo AB. New capillary growth: a contributor to regression of sclerosis? Curr Opin Nephrol Hypertens. 2005;14:201-203.
52. Fogo AB. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant. 2006;21:281-284.
53. Benigni A. Defining the role of endothelins in renal patho- physiology on the basis of selective and unselective endothelin receptor antagonist studies. Curr Opin Nephroln Hypertens. 1995;4:349-353.
54. Honing MLH, Bouter PK, Ballard DE, Padley P, Morrison PJ, Rabelink TJ. ABT-627, a selective ETA-receptor antagonist, reduce proteinuria in patients with diabetes mellitus. In: Regulation of vascular tone in humans by endothelium-derived mediators [Doctoral thesis]. University of Utrecht; 2000, p 89-102.
55. Lehrke I, Waldherr R, Ritz E, Wagner J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12:2321-2329.
56. Wenzel RR, Mann J, Jurgens C, Yildrim I, Bruck H, Philipp T, et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy [Abstract]. J Am Soc Nephrol. 2005;16:58A.
57. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorti- costerone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
58. Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension. 1995;25:1191-1195.
59. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol. 1995;115:1377-1381.
60. Fujita K, Matsumura Y, Kita S, Miyazaki Y, Hisaki K, Takaoka M, et al. Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 1995;114:925-930.
61. Fujita K, Matsumura Y, Miyazaki Y, Takaoka M, Morimoto S. Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Jpn J Pharmacol. 1996;70:313-319.
62. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, et al. Different contributions of endothelin-A and endothelin- B receptors in the pathogenesis of deoxycorticosterone acetate- salt-induced hypertension in rats. Hypertension. 1999;33:759-765.
63. Schiffrin EL, Turgeon A, Deng LY. Effect of chronic ETA- selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol. 1997;121:935-940.
64. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, et al. Ezaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation. 2000;102:2765-2773.
65. Ortiz PA, Hong NJ, Wang D, Garvin JL. Gene transfer of eNOS to the thick ascending limb of eNOS-KO mice restores the effects of L-arginine on NaCl absorption. Hypertension. 2003;42:674-679.
66. Ye Q, Chen S, Gardner DG. Endothelin inhibits NPR-A and stimulates eNOS gene expression in rat IMCD cells. Hypertension. 2003;41:675-681.
67. Herrera M, Garvin JL. Endothelin stimulates endothelial nitric oxide synthase expression in the thick ascending limb. Am J Physiol Renal Physiol. 2004;287:F231-F235.
68. Rossi NF, Beierwaltes WH. Nitric oxide modulation of ETB receptor induced vasopression release by rat and mouse hypothalamo-neurohypophyseal explants. Am J Physiol Regul Integr Comp. 2006;290:R1208-R1215.
69. Jaureguiberry MS, di Nunzio AS, Dattilo MA, Bianciotti LG, Vatta MS. Endothelin 1 and 3 enhance neuronal nitric oxide synthase activity through ETB receptors involving multiple signaling pathways in the rat anterior hypothalamus. Peptide. 2004;25:1133-1138.
70. Stricklett PK, Hughes AK, Kohan DE. Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol Renal Physiol. 2006;290:F1315-F1319.
71. b receptor-mediated regulation of nitric oxide synthase 1 (NOS1) and NOS3 isoforms in the renal inner medulla. Acta Physiol. 2007;191:329-336.